Real-world experience of adverse events with the oral PARP inhibitor niraparib in patients with platinum-sensitive recurrent ovarian cancer at a 200 mg daily dose differed from those most commonly seen in the phase 3 clinical trial at … Read more
By
A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.
Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more
The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.
PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more
Cancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.
But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more
Slamon, who is the director of both
The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504… Read more
A team of scientists from the Institute of Cancer Research in London has identified DNA mutations which makes cancer cells resistant to a new class of drugs called PARP inhibitors, used for the treatment of breast and ovarian cancers.
The … Read more
Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope.
One study found that a new targeted “immunotherapy” to treat ovarian cancer that has come back looked promising … Read more
The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more
A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more
Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more
By: Elaine Schattner
I expect progress. Here’s my list of major trends and issues that will affect the lives of cancer patients in 2018:
1. Less chemotherapy
A recent report finds that among patients with the most common form of … Read more
The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further … Read more
Join OCRFA on Monday, Oct. 23rd at 6:00pm ET for a webinar on PARP Inhibitors with Dr. Ursula Matulonis of Dana-Farber Cancer Institute.
There is a great amount of excitement in the ovarian cancer clinical and research communities about the … Read more
Women with recurrent, platinum-sensitive ovarian cancer lived twice as long without disease progression when they received maintenance therapy with the PARP inhibitor rucaparib (Rubraca), a randomized trial showed.
Overall, patients treated with rucaparib had a median progression-free survival of 10.8 … Read more
With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more
The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and combining the PARP inhibitors that accomplish that with other types of therapies will be the focus of treatment … Read more
In the treatment of advanced ovarian cancer, PARP inhibitors, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula), are stealing the limelight, explains Dennis Scribner, MD.
In an interview with Targeted Oncology, Scribner, a gynecologic oncologist at Arizona Oncology, discussed … Read more
Teri Woodhull is decidedly proactive. A strong family history of breast cancer led her to undergo a preventive bilateral mastectomy at age 30. Seventeen years later, she was diagnosed with stage 3b high-grade serous epithelial ovarian cancer.
“I do have … Read more
